Introduction
3 45 In our previous work on BEV-PEM/CIS published in Imbs et al. 2017(17) , mice with NSCLC 46 tumor xenografts were administered bevacizumab with PEM/CIS combination therapy (CT) in 47 either concomitant, or delayed (i.e. bevacizumab before PEM/CIS) scheduling. The NSCLC 48 tumors had been modified such that tumor growth could be tracked over time via either 49 bioluminescence or fluorescence. Following previous theoretical investigations, the dataset 50 generated from the mice with bioluminescent tumors was used to develop a semi-mechanistic 51 PK/PD model for tumor dynamics in response to BEV-PEM/CIS (21, 22) . The model was then 52 used to predict the optimal scheduling gap between bevacizumab and PEM/CIS administration. 53 
54
The aim of this follow-up modeling work was to both refine and expand upon previous results on 55 BEV-PEM/CIS CT using the much larger fluorescence dataset generated in Imbs et al. 56 2017(17). We first showed that the semi-mechanistic model previously developed better 57 explained the data than comparable models (i.e. we validated the previously developed 58 structural model). Then, we refined the parameter estimates of the model, and used it to predict 59 the optimal scheduling gap between bevacizumab and PEM/CIS administration. Next, we used 60 stochastic simulations to explore the marginal loss in therapeutic efficacy when BEV-PEM/CIS 61 was administered at a sub-optimal gap, the effect of bevacizumab dose scaling on population 62 optimal gap, as well as the inter-individual variability (IIV) of optimal gap. Lastly, using literature 63 human PK/PD models and parameter estimates, we were able to scale the model to estimate 64 the optimal scheduling of BEV-PEM/CIS in humans.
4 79 In addition, the BEV-PEM/CIS treatment groups were administered 20 mg/kg IP of bevacizumab 80 either concomitantly with the PEM/CIS administrations (Group 3), 3 days prior to each PEM/CIS 81 administration (Group 4), or 8 days prior to each PEM/CIS administration (Group 5)see Table   82 S1 for administration tabulation. 83 84 Tumor growth was monitored on a minimum bi-weekly basis using Ivis Spectrum imager (Perkin 85 Elmer France) and images were acquired and analyzed using the Living Image 6.0. software 86 (Perkin Elmer France). The PK models for bevacizumab, pemetrexed, and cisplatin were derived from previously 97 published PK models in mice(23-25). The parameters for these models were fixed to the typical 98 values from those studies and assumed no IIV. 99 
100
The PD model was selected from a series of sequentially fit tumor growth and drug effect 101 models. Firstusing only the control datasetthe exponential, linear-exponential, and 5 Observed vs. predicted plots, individual fit plots, and Visual Predictive Checks (VPCs) were 113 produced to graphically assist model evaluation (as automated in Monolix 2018R2). VPCs were 114 produced using the default estimation process for VPCs as of Monolix 2018R2 i.e. to create the 115 90% prediction intervals for the 10 th , 50 th , and 90 th percentiles, 500 simulations are performed 116 using random individual parameters and the design structure of the experiment. Simulating the experimental treatments with a range of administration gaps from 0 to 10 249 days (step-size = 0.1 day) suggested that the optimal time delay between scheduling 250 bevacizumab and PEM/CIS in mice is 2.0 days (Simulation set 1).
252
The simulated IIV of the optimal gap was relatively small. Only three values of individual optimal 253 gap were produced. 96.5% of the virtual animals had an individual optimal gap of 2.0 days, 254 1.0% of the virtual animals had an individual optimal gap of 2.1 days, and 2.5% of virtual 255 animals had an individual gap of 1.9 days (Simulation set 2).
257
Scaling the dosage of bevacizumab to either 30 mg/kg or 10 mg/kg produced no effect in the 258 estimated optimal gap and produced no effect in the IIV of the optimal gap (Simulation set 3). The modeling phase of the study resulted in several validations of previous findings. First, we 334 confirmed the validity of the mathematical model previously published in Imbs et al. 2017 (17), 335 which we fit to our dataset. In doing so, we reconfirmed the ability of the model to describe BEV-336 PEM/CIS scheduling. We also reconfirmed the efficacy improvement of BEV-PEM/CIS dosing 337 over PEM/CIS or control. We observed that a 3 day gap in scheduling is superior to both 338 concomitant scheduling and an 8 day gap in scheduling. We were also able to build on previous 339 work by identifying with greater precision the parameters underlying the mathematical model of We also found, through simulation, that scaling the dose of bevacizumab had no effect on the 355 optimal gap and that IIV on gap is low. The predicted scale of the increase in efficacy after scheduling optimization was much greater in 379 the human simulations than was either predicted by the mouse simulations, or was measured 380 empirically in mice. This is at least partially due to the greater study that has been undertaken in 381 optimizing dosages for human treatment of NSCLC. However, these promising estimates should 382 not be substituted for clinical testing. Mattson, 1998(39) were used to estimate population and for NSCLC in humans. The value of came from the classical assumption that a 1 mm 3 volume of tumor cells is approximately 106 cells(40). 0 was arbitrarily set to 3 cm 3 . , , , and represent volume, compartmental clearance from compartment m to compartment n, and intercompartmental clearance respectively. 
Figure 1 Structural Model Diagram
The scheme of the structural model is depicted to the right. Unperturbed cells grow at rate governed by and . When a cytotoxic is introduced into the system, the cytotoxic impairs the growth of the tumor by sending cells into a death succession. The parameter which determines the cytotoxic efficacy, , is scaled by both the concentration of cytotoxics, ( ), and the volume of the tumor, ( ). Bevacizumab improves vascular quality, ( ), after time delay, , which scales the cytotoxic effect by parameter . When a cell is damaged by cytotoxics it begins a progression from unperturbed growthcompartment ( )to damage compartments 1 through 1 . Eventually the cell exits the tumor volume as it dies. The rate of transfer between damage compartments is governed by intercompartmental clearance parameter . Blue and pink areas represent 90% prediction intervals for the 10th (blue), 50th (pink), and 90th (blue) percentiles. Prediction intervals are calculated by Monte Carlo simulation. To create prediction intervals for each unique value of time, 500 simulations are performed using random individual parameters. The red areas and red-circled points represent areas where empirical measurements fall outside of the bounds of the 90% prediction intervals.
Figure 5 Human Pharmacodynamic and Pharmacodynamic Simulations Summary
To produce these figures, bevacizumab (BEV) was administered anywhere from 0 to 10 days (in steps of 0.1) before pemetrexed/cisplatin (PEM/CIS) was administered. Tumor growth was simulated from 0 to 67 days with no IIV and no RSE. In the top figure, AUC of tumor growth vs gap (0 to 10 days) is depicted. In the middle figure, tumor dynamics over time, with gap indicated by color, are depicted. In the bottom panel, the PK of BEV-PEM/CIS is depicted with gap indicated by color. The top figure indicates that the optimal scheduling gap is 1.2 days and the middle figure depicts the difference in tumor volume between administration gaps. The patient with optimal scheduling had a final tumor volume approx. 30% the size of the concomitant scheduling.
